Sarenthia Epps, MD
Pulmonary Disease · Pine Bluff, ARNPI 1871955526
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.5% of the total across 255 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,652, more than ten times the $98 reported in 2022.
Across 255 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$698
- Actelion Pharmaceuticals US, Inc.$499
- Mallinckrodt Hospital Products Inc.$482
- Sanofi$411
- Insmed, Inc.$325
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,96393%
- Education$4017%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 71 | $1,277 |
| AstraZeneca | 34 | $698 |
| Actelion Pharmaceuticals US, Inc. | 21 | $499 |
| Mallinckrodt Hospital Products Inc. | 16 | $482 |
| Sanofi | 19 | $411 |
| Insmed, Inc. | 15 | $325 |
| Genentech USA, Inc. | 12 | $238 |
| Grifols USA, LLC | 9 | $226 |
| Viatris Specialty LLC | 8 | $176 |
| Verona Pharma, Inc. | 10 | $174 |
| Regeneron Healthcare Solutions, Inc. | 7 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $124 |
| Boehringer Ingelheim | 6 | $103 |
| Amgen | 6 | $102 |
| Mylan Specialty L.p. | 3 | $89 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| AbbVie | 3 | $68 |
| Electromed, Inc. | 2 | $63 |
| Baxter Healthcare | 2 | $35 |
| Johnson & Johnson | 1 | $18 |
| Novartis | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $14 |
| Bayer | 1 | $13 |
How this compares
$5,364 in reported general payments places this provider in the 65th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 511 | $376,972 |
| OfevNintedanib Esylate | 26 | $340,670 |
| OpsumitMacitentan | 11 | $140,974 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 96 | $61,618 |
| Dupixent PenDupilumab | 14 | $54,842 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $24,303 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $21,141 |
| SymbicortBudesonide/Formoterol Fumarate | 89 | $20,844 |
| Spiriva HandihalerTiotropium Bromide | 34 | $18,141 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $16,579 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 540 | $12,181 |
| Spiriva RespimatTiotropium Bromide | 14 | $6,921 |
| Roflumilast | 21 | $2,764 |
| Montelukast Sodium | 424 | $2,342 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $2,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,277 | $417,853600 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $103 | $368,73277 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $499 | $140,97411 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $698 | $82,462185 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Pine Bluff
- Nabeel SiddiquiPine Bluff$8K
- Ladly AbrahamConway$371K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Arturo MeadeFort Smith$67K
- Nikhil MeenaLittle Rock$63K
- Penchala MittadodlaRogers$21K
- Mark SiffordJonesboro$20K
- Zafirah SalmanNorth Little Rock$18K
- Dominika SzwedoNorth Little Rock$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.